Navigating the Maze of Hepatitis B Treatments

Gastroenterology

Volumn 132, Issue 4, 2007, Pages 1586-1594

  Lok, Anna Suk Fong ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA2B INTERFERON; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR; TYZEKA; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; NEPHROTOXICITY; PRIORITY JOURNAL;

EID: 34247268523     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.02.040     Document Type: Article

References (64)

1. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., and Lok A.S.F. Management of hepatitis B: summary of a Clinical Research Workshop. Hepatology (2007) In press
2. Ghany M., and Liang T.J. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 132 (2007) 1574-1585
3. Wong D.K., Cheung A.M., O'Rourke K., Naylor C.D., Detsky A.S., and Heathcote J. Effect of α-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. (comments). Ann Intern Med 119 (1993) 312-323
4. Cooksley W.G., Piratvisuth T., Lee S.D., Mahachai V., Chao Y.C., Tanwandee T., Chutaputti A., et al. Peginterferon α-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10 (2003) 298-305
5. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., Gane E., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
6. Marcellin P., Lau G.K., Bonino F., Farci P., Hadziyannis S., Jin R., Lu Z.M., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 (2004) 1206-1217
7. Janssen H.L., van Zonneveld M., Senturk H., Zeuzem S., Akarca U.S., Cakaloglu Y., Simon C., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (2005) 123-129
8. Lai C.L., Chien R.N., Leung N.W., Chang T.T., Guan R., Tai D.I., Ng K.Y., et al., Asia Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. (comments). N Engl J Med 339 (1998) 61-68
9. Dienstag J.L., Schiff E.R., Wright T.L., Perrillo R.P., Hann H.W., Goodman Z., Crowther L., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341 (1999) 1256-1263
10. Marcellin P., Chang T., Lim S.G., Tong M., Sievert W., Schiffman M., Jeffers L., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
11. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., Marcellin P., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
12. Lai C.L., Shouval D., Lok A.S., Chang T.T., Cheinquer H., Goodman Z., DeHertogh D., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006) 1011-1020
13. Chang T.T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.C., Lok A.S., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
14. Schalm S.W., Heathcote J., Cianciara J., Farrell G., Sherman M., Willems B., Dhillon A., et al. Lamivudine and α interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. (comments). Gut 46 (2000) 562-568
15. Lai C., Gane E., Liaw Y.-F., Thongawat S., Wang Y., Heathcote E., Rasenack J., et al. Telbivudine (LDT) vs. lamivudine for chronic hepatitis B: first-year results from the International Phase III Globe Trial. Hepatology 42 (2005) 748A
16. Dienstag J.L., Cianciara J., Karayalcin S., Kowdley K.V., Willems B., Plisek S., Woessner M., et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 37 (2003) 748-755
17. Song B.C., Suh D.J., Lee H.C., Chung Y.H., and Lee Y.S. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32 (2000) 803-806
18. Ryu S.H., Chung Y.H., Choi M.H., Kim J.A., Shin J.W., Jang M.K., Park N.H., et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 39 (2003) 614-619
19. Lok A.S., Lai C.L., Leung N., Yao G.B., Cui Z.Y., Schiff E.R., Dienstag J.L., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
20. Chang T.T., Lai C.L., Chien R.N., Guan R., Lim S.G., Lee C.M., Ng K.Y., et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 19 (2004) 1276-1282
21. Marcellin P., Chang T., Lim S.G., Sievert W., Tong M., Arterburn S., Borroto-Esoda K., et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients. (abstr 969). Hepatology 44 (2006) 548A
22. Chang T., Chao Y.-C., Kaymakoglu S., Cheinquer H., Pessoa M., Gish R., Poordad F., et al. Entecavir maintained virologic suppression through 3 years of treatment in antiviral naive HBeAg(+) Patients (ETV 022/901). (abstr 109). Hepatology 44 (2006) 229A
23. Hadziyannis S., Tassopoulos N., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., Marcellin P., et al. Long-term (3-year) therapy with adefovir dipivoxil for the treatment of hepatitis B e antigen negative chronic hepatitis B. N Eng J Med 352 (2005) 2673-2681
24. Marcellin P., Bonino F., Lau G., Farci P., Yurdaydin C., Piratvisuth T., Luo K., et al. Suppression of HBV DNA in patients with HBeAg-negative CHB treated with peginterferon alfa-2A (40 KD) ± lamivudine: 2-year follow-up results. (abstr 972). Hepatology 44 (2006) 550A
25. Papatheodoridis G.V., Dimou E., Laras A., Papadimitropoulos V., and Hadziyannis S.J. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 36 (2002) 219-226
26. Hadziyannis S., Tassopoulos N., Heathcote E., Chang T., Kitis G., Rizzetto M., Marcellin P., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
27. Sung J.J.Y.L.J., Zeuzem S., Chow W.C., Heathcote E., Perrillo R., Brosgart C., et al. A randomized double-blind phase II study of lamivudine compared to lamivudine plus adefovir dipivoxil for treatment naïve patients with chronic hepatitis B: week 52 analysis. J Hepatol 38 Suppl2 (2003) 25 (abstr)
28. A phase II study of lamivudine compared to lamivudine plus adefovir dipivoxil for subjects with chronic hepatitis B. Available at: http://ctr.gsk.co.uk/Summary/lamivudine/II_NUC20912. Accessed December 1, 2006.
29. Lai C.L., Leung N., Teo E.K., Tong M., Wong F., Hann H.W., Han S., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
30. Lau G., Cooksley H., Ribeiro R.M., Powers K.A., Bowden S., Mommeja-Marin H., Mondou E., et al. Randomized, double-blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg(+) chronic hepatitis B: efficacy and mechanisms of treatment response. (abstr 245). Hepatology 40 (2004) 272A
31. Yang H., Qi X., Sabogal A., Miller M., and Delaney IV W.E. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 10 (2005) 625-633
32. Peters M.G., Andersen J., Lynch P., Liu T., Alston-Smith B., Brosgart C.L., Jacobson J.M., et al. Viral hepatitis: randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 44 (2006) 1110-1116
33. van Bommel S., Zollner B., Sarrazin C., Spengler U., Huppe D., Moller B., Feucht H.H., et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 44 (2006) 318-325
34. Lim S.G., Ng T.M., Kung N., Krastev Z., Volfova M., Husa P., Lee S.S., et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 166 (2006) 49-56
35. Marcellin P., Mommeja-Marin H., Sacks S.L., Lau G.K., Sereni D., Bronowicki J.P., Conway B., et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 40 (2004) 140-148
36. Lee Y., Suh D., Lim Y., Jung S., Kim K., Lee H., Chung Y., et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43 (2006) 1385-1391
37. Hoofnagle J.H., Di Bisceglie A.M., Waggoner J.G., and Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 104 (1993) 1116-1121
38. Perrillo R., Tamburro C., Regenstein F., Balart L., Bodenheimer H., Silva M., Schiff E., et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 109 (1995) 908-916
39. Fontana R.J., Hann H.W., Perrillo R.P., Vierling J.M., Wright T., Rakela J., Anschuetz G., et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 123 (2002) 719-727
40. Hadziyannis S., Tassopoulos N., Chang T.T., Heathcote J., Kitis G., Rizzetto M., Marcellin P., et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy. Hepatology 42 (2005) 754A
41. Colonno R., Rose R., Pokornowski K., Baldick C., Klesczewski K., and Tenney D. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients. (abstr 110). Hepatology 44 (2006) 229A-230A
42. Lai C., Gane E., Hsu C.-W., Thonsgawat S., Wang Y., Chen Y., Heathcote E., et al. Two-year results from the Globe Trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine. (abstr 91). Hepatology 44 (2006) 222A
43. Sherman M., Martin P., Lee W., Yurdaydin C., Sollano J., Vaughan J., and Hindes R. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026). (abstr). Gastroenterology 130 Suppl 2 (2006) A765
44. Yim H.J., Hussain M., Liu Y., Wong S.N., Fung S., and Lok A. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44 (2006) 703-712
45. Niederau C., Heintges T., Lange S., Goldmann G., Niederau C.M., Mohr L., and Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. (comments). N Engl J Med 334 (1996) 1422-1427
46. Lau D.T., Everhart J., Kleiner D.E., Park Y., Vergalla J., Schmid P., and Hoofnagle J.H. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113 (1997) 1660-1667
47. van Zonneveld M., Honkoop P., Hansen B., Niesters G., Murad S., de Man R., Schalm S., et al. Viral hepatitis: long-term follow-up of α-interferon treatment of patients with chronic hepatitis B. Hepatology 33 (2004) 804-810
48. Papatheodoridis G.V., Manesis E., and Hadziyannis S.J. The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 34 (2001) 306-313
49. Lin S.M., Sheen I.S., Chien R.N., Chu C.M., and Liaw Y.F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29 (1999) 971-975
50. Yuen M.F., Hui C.K., Cheng C.C., Wu C.H., Lai Y.P., and Lai C.L. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 34 (2001) 139-145
51. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., Tanwandee T., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
52. Yim H.J., and Lok A.S. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43 (2006) S173-S181
53. Lok A.S., and McMahon B. Practice guidelines: chronic hepatitis B. Hepatology 45 (2007) 507-539
54. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., Huang G.T., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
55. Iloeje U., Yang H., Su J., Jen C., You S., and Chen C. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
56. Prati D., Taioli E., Zanella A., Della Torre E., Butelli S., Del Vecchio E., Vianello L., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002) 1-10
57. Ware J. The limitations of risk factors as prognostic tools. N Engl J Med 355 (2006) 2615-2617
58. Lok A.S., Schiff E., Tsai N., Rustgi V., Schiffman M., Martin P., Boyer T., et al. Entecavir is effective irrespective of baseline Alt and HBV DNA strata for histological and virological endpoints. Gastroenterology 128 Suppl 2 (2005) 194
59. Wai C.T., Chu C.J., Hussain M., and Lok A.S. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 36 (2002) 1425-1430
60. Flink H., van Zonneveld M., Hansen B., de Man R., Schalm S., Janssen H., and Group. H-S. Treatment with Peg-interferon α-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 101 (2006) 297-303
61. Fung S.K., Chae H.B., Fontana R.J., Conjeevaram H., Marrero J., Oberhelman K., Hussain M., et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44 (2006) 283-290
62. Lampertico P., Vigano M., Manenti E., Iavarone M., Lunghi G., and Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developin genotypic resistance to lamivudine. Hepatology 42 (2005) 1414-1419
63. Gish R., Chang T.T., de Man R., Gadano A., Sollano J., Han K.H., Lok A., et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (Study ETV-022). Hepatology 42 (2005) 267A
64. Fung S.K., Wong F., Hussain M., and Lok A.S. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 11 (2004) 432-438